Back Back
Cell No. : Cell Name
RCB1900 : Lu99  update : 2024/04/16
CommentLung giant cell carcinoma cell line derived from human. TKG0495 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Obinata, Masuo
Originator Hirohashi, S. and Shimosatao, Y.
Year of deposit 2004
Original cell TKG0495
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 63 years
Tissue lung
Disease name Giant cell carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0495)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_3015
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 53-58(50) : 53(5),54(9),55(12),56(12),57(6),58(6)
STR(human) OK
deposit info
lot info
Reference information Reference 1
User's Publication 22

To topTop
2856  Yamada T, Hirohashi S, Shimosato Y, Kodama T, Hayashi S, Ogura T, Gamou S, Shimizu N  Giant cell carcinomas of the lung producing colony-stimulating factor in vitro and in vivo.  Jpn J Cancer Res  1985  76:967-76  PubMed ID: 3935627  

To topTop
User's Publication
19670  Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, Trinh D, Hebbert A, Smith CR, Kulyk S, Lawson JD, He L, Hover LD, Fernandez-Banet J, Hallin J, Vanderpool D, Briere DM, Blaj A, Marx MA, Rodon J, Offin M, Arbour KC, Johnson ML, Kwiatkowski DJ, Jänne PA, Haddox CL, Papadopoulos KP, Henry JT, Leventakos K, Christensen JG, Shazer R, Olson P.  MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer  Cancer Discov  2023  13(11):2412-2431  PubMed ID: 37552839   DOI: 10.1158/2159-8290.CD-23-0669
21465  Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M, Kottarathil T, Piquet M, Cao Y, Martinuzzi-Duboc L, Buhles A, Alder F, Mannino S, Tordella L, Sansregret L, Maira SM, Graus Porta D, Fedele C, Brachmann SM.  CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer.  Cancer Res  2023    PubMed ID: 37934115   DOI: 10.1158/0008-5472.CAN-23-1127
17631  Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy SR, Gainor JF, Rajan AP, Nieblas-Bedolla E, Burns AC, Hallin J, Olson P, Christensen JG, Kurz SC, Brastianos PK, Wakimoto H.  Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer  Clin Cancer Res  2022  28(15):3318-3328  PubMed ID: 35404402   DOI: 10.1158/1078-0432.CCR-22-0383
20534  Smith CR, Aranda R, Bobinski TP, Briere DM, Burns AC, Christensen JG, Clarine J, Engstrom LD, Gunn RJ, Ivetac A, Jean-Baptiste R, Ketcham JM, Kobayashi M, Kuehler J, Kulyk S, Lawson JD, Moya K, Olson P, Rahbaek L, Thomas NC, Wang X, Waters LM, Marx MA.  Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.  J Med Chem  2022    PubMed ID: 35041419   DOI: 10.1021/acs.jmedchem.1c01900
20913  Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM.  PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.  Br J Cancer  2022    PubMed ID: 36319849   DOI: 10.1038/s41416-022-02032-w
16801  Minegishi K, Dobashi Y, Tsubochi H, Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y, Endo S.  TFF-1 Functions to Suppress Multiple Phenotypes Associated with Lung Cancer Progression  Onco Targets Ther  2021  14:4761-4777  PubMed ID: 34531663   DOI: 10.2147/OTT.S322697
13304  Colombo M, Marabese M, Vargiu G, Broggini M, Caiola E.  Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.  Front Oncol  2020    PubMed ID: 33194590   DOI: 10.3389/fonc.2020.532292
13773  Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.  Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites  Cancer Sci  2020  111(2):667-678  PubMed ID: 31828882   DOI: 10.1111/cas.14278
13841  Eguchi R, Wakabayashi I.  HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer  Oncol Rep  2020  44(1):14-28  PubMed ID: 32319650   DOI: 10.3892/or.2020.7580
13925  Iezzi A, Caiola E, Colombo M, Marabese M, Broggini M.  Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines  Am J Cancer Res  2020  10(12):4488-4497  PubMed ID: 33415013  
15895  Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG.  The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients  Cancer Discov  2020  10(1):54-71  PubMed ID: 31658955   DOI: 10.1158/2159-8290.CD-19-1167
11496  Miyake N, Chikumi H, Yamaguchi K, Takata M, Takata M, Okada K, Kitaura T, Nakamoto M, Yamasaki A.  Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness.  Yonago Acta Med  2019    PubMed ID: 30962749   DOI: 10.33160/yam.2019.03.012
4280  Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M.  Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.  Molecules  2018    PubMed ID: 30126206   DOI: 10.3390/molecules23082071
7006  Iida K, Sakai R, Yokoyama S, Kobayashi N, Togo S, Yoshikawa HY, Rawangkan A, Namiki K, Suganuma M.  Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.  Sci Rep  2017  7:17770  PubMed ID: 29259259   DOI: 10.1038/s41598-017-18120-4
14222  Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T.  Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC  Mol Cancer Res  2017  15(10):1354-1365  PubMed ID: 28698358   DOI: 10.1158/1541-7786.MCR-17-0191
14130  Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis  Cell Rep  2016  15(3):574-587  PubMed ID: 27068473   DOI: 10.1016/j.celrep.2016.03.043
7462  Tomita T, Ieguchi K, Sawamura T, Maru Y.  Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor.  PLoS ONE  2015  10:e0118835  PubMed ID: 25738827   DOI: 10.1371/journal.pone.0118835
15129  Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y.  Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity  J Med Chem  2015  58(4):1760-75  PubMed ID: 25625617   DOI: 10.1021/jm501599u
9106  Seo SK, Hwang CS, Choe TB, Hong SI, Yi JY, Hwang SG, Lee HG, Oh ST, Lee YH, Park IC.  Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation  Oncotarget  2015  6(28):26528-40  PubMed ID: 25605253   DOI: 10.18632/oncotarget.3100
5833  Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, Yano H, Sannomiya K, Goji T, Miyamoto H, Okahisa T, Mikasa H, Wada S, Iwata M, Takayama T.  High antitumor activity of pladienolide B and its derivative in gastric cancer.  Cancer Sci  2014  105(1):110-6  PubMed ID: 24635824   DOI: 10.1111/cas.12317
15715  Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H.  Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma  PLoS One  2011  6(9):e25301  PubMed ID: 21966491   DOI: 10.1371/journal.pone.0025301
16553  Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer  J Transl Med  2011  9:191  PubMed ID: 22053850   DOI: 10.1186/1479-5876-9-191

Back Back Return Top Page